Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA
Open Access
- 23 September 2014
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Urology
- Vol. 11 (10), 589-596
- https://doi.org/10.1038/nrurol.2014.245
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Therapeutic Outcome of Fluorescence Cystoscopy Guided Transurethral Resection in Patients with Non-Muscle Invasive Bladder Cancer: A Meta-Analysis of Randomized Controlled TrialsPLOS ONE, 2013
- The Costs of Non-Muscle Invasive Bladder CancerUrologic Clinics of North America, 2013
- Long-Term Decrease in Bladder Cancer Recurrence with Hexaminolevulinate Enabled Fluorescence CystoscopyJournal of Urology, 2012
- An evaluation to define the role of repeat transurethral resection in a treatment algorithm for non-muscle-invasive bladder cancerIndian Journal of Urology, 2012
- Role of hexaminolevulinate-guided fluorescence cystoscopy in bladder cancer: critical analysis of the latest data and European guidanceScandinavian Journal of Urology and Nephrology, 2011
- The value of a second transurethral resection for T1 bladder cancerBJU International, 2006
- Hexyl AminolevulinateDrugs, 2006
- Second Transurethral Resection of Superficial Transitional Cell Carcinoma of the Bladder: A Must Even for Experienced UrologistsUrologia Internationalis, 2004
- Effect of Routine Repeat Transurethral Resection for Superficial Bladder Cancer: A Long-term Observational StudyJournal of Urology, 2003
- SECOND RESECTION AND PROGNOSIS OF PRIMARY HIGH RISK SUPERFICIAL BLADDER CANCER: IS CYSTECTOMY OFTEN TOO EARLY?Journal of Urology, 2001